Keyphrases
Confidence Interval
100%
Systematic Meta-analysis
100%
Pooled Analysis
100%
Real-world Experience
100%
Vedolizumab
100%
Clinical Remission
40%
Crohn's Disease
30%
Ulcerative Colitis
30%
Clinical Response
30%
Experiential Research
30%
Crohn's Colitis
20%
Monoclonal Antibody
10%
Adverse Effects
10%
Clinical Setting
10%
Safety Profile
10%
Adult Patients
10%
Induction Treatment
10%
Narrative Review
10%
Maintenance Treatment
10%
Anti-integrin
10%
Adult Cohort
10%
Safety Data
10%
Efficacy Data
10%
Medicine and Dentistry
Systematic Review
100%
Pooled Analysis
100%
Vedolizumab
100%
Inflammatory Bowel Disease
100%
Ulcerative Colitis
71%
Crohn's Disease
71%
Infection
14%
Monoclonal Antibody
14%
Personal Experience
14%
Maintenance Therapy
14%
Adverse Effect
14%
Integrin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
100%
Vedolizumab
100%
Crohn's Disease
71%
Ulcerative Colitis
71%
Remission
57%
Infection
14%
Monoclonal Antibody
14%
Integrin
14%
Neuroscience
Inflammatory Bowel Disease
100%
Vedolizumab
100%
Adverse Effect
14%
Monoclonal Antibody
14%
Integrin
14%